| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Resveratrol, also known as trans-Resveratrol, SRT-501 and RM-1812, is a naturally occuring phytoalexin produced by several plants with anti-cancer, antioxidant, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces phase II drug-metabolizing enzymes and induces promyelocytic leukemia cell differentiation, thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner.
| ln Vitro |
Resveratrol (trans-Resveratrol; SRT501) is one of numerous polyphenolic chemicals found in a range of plant sources. In the vast majority of cases, Resveratrol demonstrates inhibitory/activating effects in the micromolar range, which may be pharmacologically feasible, although targets in the nanomolar range have also been described [1]. MCF-7 cells were plated in DME-F12 media supplemented with 5% FBS and increasing doses of Resveratrol. Control cells were treated with the same volume of vehicle (0.1% ethanol) alone. Resveratrol suppresses the development of MCF-7 cells in a dose-dependent way. Addition of 10 μM Resveratrol resulted in 82% suppression of MCF-7 cell growth after 6 days, but at 1 μM, only 10% inhibition was seen. Cells treated with 10 μM Resveratrol had a doubling time of 60 hours, whereas control cells doubled every 30 hours. Trypan blue exclusion assay demonstrated that at concentrations of 10 μM or below, Resveratrol did not impair cell viability (90% of viable cells), however at a dose of 100 μM, only 50% of cells survived after 6 days of Resveratrol administration. In addition, MCF-7 cells did not undergo apoptosis after incubation with Resveratrol at a dosage of 10 μM, as assessed by the ApoAlert Annexin V Apoptosis Kit [2]. Resveratrol promotes nitric oxide (NO) production in endothelial cells by upregulating the expression of endothelial nitric oxide synthase (eNOS), boosting eNOS enzyme activity, and blocking eNOS uncoupling [7].
|
||
|---|---|---|---|
| ln Vivo |
Treatment with resveratrol (trans-Resveratrol; SRT501) at 50 mg/kg (195.5±124.8 mm3; P<0.05) or 100 mg/kg reduced the mean tumor volume (81.7±70.5 mm3; P<0.001). Tumor mass and volume have a strong correlation [3].
|
||
| Animal Protocol |
|
||
| References |
Nat Rev Drug Discov.2006 Jun;5(6):493-506.
|
| Molecular Formula |
C14H12O3
|
|---|---|
| Molecular Weight |
228.24
|
| CAS # |
501-36-0
|
| Related CAS # |
Resveratrol;501-36-0
|
| SMILES |
OC1=CC(/C=C/C2=CC=C(O)C=C2)=CC(O)=C1
|
| Chemical Name |
(E)-5-(4-hydroxystyryl)benzene-1,3-diol
|
| Synonyms |
SRT-501; RM-1812; SRT 501; RM 1812; SRT501; RM1812; trans-Resveratrol; CA1201; CA-1201; CA 1201; Resvida; Vineatrol 20M.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (21.91 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (21.91 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (21.91 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 8: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 9: 2% DMSO+30% PEG 300+ddH2O: 5mg/mL Solubility in Formulation 10: 12.5 mg/mL (54.77 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 11: 16.67 mg/mL (73.04 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3814 mL | 21.9068 mL | 43.8135 mL | |
| 5 mM | 0.8763 mL | 4.3814 mL | 8.7627 mL | |
| 10 mM | 0.4381 mL | 2.1907 mL | 4.3814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06020313 | Recruiting | Dietary Supplement: Resveratrol Experimental |
Polyphenols Cardiovascular Diseases |
Taisy Cinthia Ferro Cavalcante | August 2023 | Not Applicable |
| NCT05874882 | Recruiting | Other: resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients |
Periodontitis | University of Baghdad | December 12, 2022 | Early Phase 1 |
| NCT06250283 | Recruiting | Dietary Supplement: Resveratrol Dietary Supplement: Placebo |
Low Bone Mass | University of Delaware | February 2, 2024 | Not Applicable |
| NCT03933163 | Active, not recruiting | Drug: Resveratrol | Friedreich Ataxia | Murdoch Childrens Research Institute | May 23, 2019 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA